Sugi Predict

Sugi Predict / Targets / SLC16A7

SLC16A7

Monocarboxylate transporter 2 · O60669 · SLC16A7 on Sugi Atlas →

671 patent compounds predicted against SLC16A7, 609 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Msc-4381 Msc-4381 (SCHEMBL22116621) 1.00 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL30148484) 1.00 1/20
SCHEMBL29818663 SCHEMBL29818663 0.98 1/20
SCHEMBL22116778 SCHEMBL22116778 0.90 1/20
SCHEMBL22116703 SCHEMBL22116703 0.89 1/20
SCHEMBL22116501 SCHEMBL22116501 0.84 1/20
SCHEMBL22116679 SCHEMBL22116679 0.83 1/20
SCHEMBL30188226 SCHEMBL30188226 0.83 1/20
SCHEMBL5864717 SCHEMBL5864717 0.78 1/20
SCHEMBL22116779 SCHEMBL22116779 0.78 1/20
SCHEMBL30182486 SCHEMBL30182486 0.77 1/20
SCHEMBL24109639 SCHEMBL24109639 0.77 1/20
SCHEMBL22116838 SCHEMBL22116838 0.76 1/20
SCHEMBL22116531 SCHEMBL22116531 0.75 1/20
SCHEMBL3826394 SCHEMBL3826394 0.74 1/20
SCHEMBL3826398 SCHEMBL3826398 0.74 1/20
SCHEMBL3827013 SCHEMBL3827013 0.74 1/20
SCHEMBL22116761 SCHEMBL22116761 0.74 1/20
SCHEMBL22116629 SCHEMBL22116629 0.74 1/20
SCHEMBL30188269 SCHEMBL30188269 0.74 1/20

Clinical trials — most relevant to SLC16A7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Genetic Basis for Variation in the Renal Elimination of Metformin PHASE4COMPLETED
Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m PHASE3COMPLETED
Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome) PHASE2/PHASE3UNKNOWN
Reformulated F75 Milk to Treat Severe Acute Malnutrition PHASE2/PHASE3COMPLETED
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors PHASE2ACTIVE_NOT_RECRUITING
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) PHASE1COMPLETED
Multi-Tracer PET Assessment of Primary Brain Tumors PHASE1COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I EARLY_PHASE1COMPLETED
Sodium Lactate Infusion in GLUT1DS Patients EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors nanUNKNOWN
Erythrocyte Transport of Lactate During Exercise (TELE Project) nanRECRUITING
Register for Patients With Thyroid Hormone Resistance. nanRECRUITING
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome nanACTIVE_NOT_RECRUITING
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis nanRECRUITING
Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment nanCOMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Glutamate Supplementation in Young Men nanCOMPLETED
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore nanCOMPLETED
Fluorescence and Glioma Heterogeneity nanCOMPLETED
Identifying Diuretic Resistance in Patients With Acute Heart Failure nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC16A7 binder may also engage these)

ProteinNameSimilarity
P53988 — 0.997 P53988 →
P53986 — 0.992 P53986 →
Q3MHW6 — 0.992 Q3MHW6 →
Q03064 — 0.988 Q03064 →
SLC16A1 Monocarboxylate transporter 1 0.988 landscape →
P53987 — 0.987 P53987 →
P57788 — 0.984 P57788 →
O35910 — 0.974 O35910 →
P57787 — 0.974 P57787 →
O35440 — 0.973 O35440 →
O70451 — 0.968 O70451 →
Q63344 — 0.965 Q63344 →
SLC16A3 Monocarboxylate transporter 4 0.959 landscape →
G5E8K6 — 0.948 G5E8K6 →
Q90632 — 0.948 Q90632 →
Q58CV5 — 0.946 Q58CV5 →
Q9WU81 — 0.943 Q9WU81 →
Q27963 — 0.942 Q27963 →
Q8BRU6 — 0.942 Q8BRU6 →
Q01818 — 0.940 Q01818 →
B0JZE1 — 0.939 B0JZE1 →
Q01827 — 0.938 Q01827 →
SLC18A1 Chromaffin granule amine transporter 0.938 landscape →
Q8TED4 — 0.938 Q8TED4 →
Q7SY29 — 0.937 Q7SY29 →
Q8R090 — 0.936 Q8R090 →
F1NCD6 — 0.936 F1NCD6 →
SLC18A2 Synaptic vesicular amine transporter 0.934 landscape →
Q8TF71 — 0.931 Q8TF71 →
Q8VCV9 — 0.931 Q8VCV9 →